Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa A Hammond

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patientsShazli N Malik, Lillian L Siu, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor propertiesSamira Syed, Chris Takimoto, Manuel Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson, Lisa A Hammond, David Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patientsShazli N Malik, Lillian L Siu, Eric K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor propertiesSamira Syed, Chris Takimoto, Manuel Hidalgo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2003
A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignanciesBahram Forouzesh, Chris H Takimoto, Andrew Goetz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, John Kuhn, Garry Schwartz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trialMalcolm Ranson, Lisa A Hammond, David Ferry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignanciesJohann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignanciesEric K Rowinsky, Jinee Rizzo, Leonel Ochoa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2004
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect studyEmiliano Calvo, Anthony W Tolcher, Lisa A Hammond, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignanciesAmita Patnaik, Eric K Rowinsky, Miguel A Villalona, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumorsAlejandro D Ricart, Lisa A Hammond, John G Kuhn, et al.
Pageof 4